Schedule 13G ownership disclosure
Avalo Therapeutics, Inc.
Class A Common Stock · CUSIP: 05338F306
Event date: 2025-12-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- SilverArc Capital Management, LLC
Shares: 524,436.00 · Class: 2.83%
- Devesh Gandhi
Shares: 524,436.00 · Class: 2.83%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001104659-26-012459
- Form type
- SCHEDULE 13G
- Filer
- Avalo Therapeutics, Inc.
- CIK
- CIK 1534120
- Filed
- Feb 10, 2026
- Reporting period
- Dec 31, 2025
- Description
- Schedule 13G beneficial ownership